Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$25.15 USD
+0.49 (1.99%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $25.11 -0.04 (-0.16%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth C Momentum C VGM
Earnings News For PTGX
-
Protagonist Therapeutics: Q4 Earnings Snapshot
-
Protagonist Therapeutics: Q3 Earnings Snapshot
-
Protagonist Therapeutics: Q1 Earnings Snapshot
-
Protagonist Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
Protagonist Therapeutics: Q4 Earnings Snapshot
-
Protagonist Therapeutics: Q3 Earnings Snapshot
-
Protagonist Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates
-
Protagonist Therapeutics: Q2 Earnings Snapshot
-
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
-
Protagonist Therapeutics (PTGX) Reports Q4 Loss, Tops Revenue Estimates
-
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates
-
Analysts Estimate Protagonist Therapeutics (PTGX) to Report a Decline in Earnings: What to Look Out for
-
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates
-
Will Protagonist Therapeutics (PTGX) Report Negative Q2 Earnings? What You Should Know
-
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
-
Protagonist Therapeutics (PTGX) Reports Q4 Loss, Tops Revenue Estimates
-
Will Protagonist Therapeutics (PTGX) Report Negative Q4 Earnings? What You Should Know
-
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates
-
Protagonist Therapeutics (PTGX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
-
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Tops Revenue Estimates
-
Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
-
Protagonist Therapeutics (PTGX) Reports Q4 Loss, Lags Revenue Estimates
-
Analysts Estimate Protagonist Therapeutics (PTGX) to Report a Decline in Earnings: What to Look Out for
-
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates